Category Archives: Stem Cells

Case Stem SE2
Buy from Amazon US redirect.viglink.com?key=f341fd9454fc162be8b38d504acbd4e1 out=http%3A%2F%2Fwww%2Eamazon%2Ecom%2Fexec%2Fobidos%2FASIN%2FB007OWHFUK%2Fhealth%5Fhope%2D20 Product Description Case Stem SE2 Stemtech #39;s SE2TM is the world #39;s first all-natural supplement documented to support the release of adult stem cells from bone marrow. Our advanced supplement puts more stem cells in the bloodstream, and the effect lasts longer Disclaimer Hope is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon. Amazon and the Amazon logo are trademarks of Amazon, Inc. or its affiliates.From:yasuko tilleyViews:0 0ratingsTime:00:56More inEducation

See original here:
Case Stem SE2 - Video

[2 Royal
Buy from Amazon US redirect.viglink.com?key=f341fd9454fc162be8b38d504acbd4e1 out=http%3A%2F%2Fwww%2Eamazon%2Ecom%2Fexec%2Fobidos%2FASIN%2FB007ILI394%2Fhealth%5Fhope%2D20 Product Description [2 Royal This is for 2 bottles of Royal Jelly 1000mg 360s. [[Function It has been reported as a possible immunomodulatory agent. It has also been reported to stimulate the growth of glial cells and neural stem cells in the brain, which may relate to claims for its use as a longer-term cognitive enhancer and as a beneficial agent in cases of Parkinson #39;s Disease.]] --- [[Ingredients: Pure Natural Royal Jelly 1000mg]] --- [[Other Ingredients: gelatin, soy lecithin, glycerin and yellow beeswax]] --- [[Directions: For adults, take one (1) softgel one to three times daily, preferably with a meal. If you have never taken bee products, start with a small serving per day and increase gradually in order to assess whether you are allergic.]] --- [[Store Retail Price: 131.98 per bottle]] Disclaimer: Hope is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon. Amazon and the Amazon logo are trademarks of Amazon, Inc. or its affiliates.From:mikaela gomesViews:0 0ratingsTime:00:58More inScience Technology

Original post:
[2 Royal - Video

sct process
This video is demonstrating the stem cells development process at StemRx Bio Science SolutionsFrom:Pradeep MahajanViews:0 0ratingsTime:03:00More inScience Technology

See the original post:
sct process - Video

ScienceDaily (Nov. 15, 2012) Researchers and patients look forward to the day when stem cells might be used to replace dying brain cells in Alzheimer's disease and other neurodegenerative conditions. Scientists are currently able to make neurons and other brain cells from stem cells, but getting these neurons to properly function when transplanted to the host has proven to be more difficult. Now, researchers at Sanford-Burnham Medical Research Institute have found a way to stimulate stem cell-derived neurons to direct cognitive function after transplantation to an existing neural network.

The study was published November 7 in the Journal of Neuroscience.

"We showed for the first time that embryonic stem cells that we've programmed to become neurons can integrate into existing brain circuits and fire patterns of electrical activity that are critical for consciousness and neural network activity," said Stuart A. Lipton, M.D., Ph.D., senior author of the study. Lipton is director of Sanford-Burnham's Del E. Webb Neuroscience, Aging, and Stem Cell Research Center and a clinical neurologist.

The trick turned out to be light. Lipton and his team -- including Juan Pia-Crespo, Ph.D., D.V.M., Maria Talantova, M.D., Ph.D., and other colleagues at Sanford-Burnham and Stanford University -- transplanted human stem cell-derived neurons into a rodent hippocampus, the brain's information-processing center. Then they specifically activated the transplanted neurons with optogenetic stimulation, a relatively new technique that combines light and genetics to precisely control cellular behavior in living tissues or animals.

To determine if the newly transplanted, light-stimulated human neurons were actually working, Lipton and his team measured high-frequency oscillations in existing neurons at a distance from the transplanted ones. They found that the transplanted neurons triggered the existing neurons to fire high-frequency oscillations. Faster neuronal oscillations are usually better -- they're associated with enhanced performance in sensory-motor and cognitive tasks.

To sum it up, the transplanted human neurons not only conducted electrical impulses, they also roused neighboring neuronal networks into firing -- at roughly the same rate they would in a normal, functioning hippocampus.

The therapeutic outlook for this technology looks promising. "Based on these results, we might be able to restore brain activity -- and thus restore motor and cognitive function -- by transplanting easily manipulated neuronal cells derived from embryonic stem cells," Lipton said.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

Read more:
Neurons made from stem cells drive brain activity after transplantation in laboratory model

San Diego biotechnology and civic leaders threw their support behind stem cell research eight years ago, when the states voters approved Proposition 71, the $3 billion state stem cell initiative.

Californians were promised that the research would lead to therapies for diseases and injuries that had no cure, such as spinal paralysis and diabetes. Once scientists had done the research, biotech companies in the field known as regenerative medicine would take over and bring the therapies to market.

San Diego research centers banded together to bring in stem cell grants, getting more than $261 million. Local leaders calculated there would be commercial benefits as well, reinforcing San Diegos stature as one of the worlds top biotech centers.

Now, that commercialization is starting to take place. Local biotechs are testing stem cell therapies in patients, in the United States, in Europe and in China.

Cures for diabetes, heart failure, and even baldness are being developed by San Diego companies; the last two already being tested in patients. While these treatments are still experimental success is far from certain they provide a preliminary indication that regenerative medicine is on the road to becoming a new growth area for the regions large biotechnology industry.

About a dozen San Diego-based companies, such as ViaCyte, Histogen and Medistem, are working on treatments with various kinds of stem cells, the ancestral cells that give rise to the various cells in the body. Some are using cells derived from human embryos, still a controversial practice to many. But most others are using cells derived from nonembryonic sources, such as skin and umbilical cord blood.

These treatments are mostly in the early stages of clinical trials; meaning they will take years to get approval. But at least one local company, Cytori Therapeutics, has begun a pivotal trial of its stem cell treatment for heart failure, in Europe. A pivotal trial is designed to get the statistically significant evidence of effectiveness needed for regulatory approval.

Other San Diego stem cell companies conducting clinical trials include Medistem, for heart attack and heart failure patients; Fate Therapeutics, for blood stem cell transplantation; and Stemedica for heart attacks. ViaCyte is preparing to start a clinical trial with its own stem cell-based diabetes treatment, bolstered by a $10.1 million grant last month from the states stem cell agency, the California Institute for Regenerative Medicine.

To illustrate the challenges and opportunities facing local stem cell companies, the stories of Histogen, Medistem and Cytori are instructive. Histogen combines scientific acumen with hard-won business experience; Medistem has developed a technology around a special kind of stem cell; and Cytori has turned fat into something to be desired.

Gail Naughton, Histogens chief executive, learned about the promise and pitfalls of regenerative medicine at Advanced Tissue Sciences. Naughton, who holds a doctorate in hematology, founded the privately held company in New York in 1986 and later moved it to San Diego.

Go here to see the original:
Showtime for stem cells at San Diego biotechs

ScienceDaily (Nov. 14, 2012) Environmental contaminants, such as smoking, are harmful to the human organism in relation to the occurrence of allergies. This is known. Until now, researchers had never investigated whether and to what extent environmental contaminants also affect allergy-relevant stem cells. For the first time a team at the Helmholtz Centre for Environmental Research (UFZ) has found evidence for this: Smoking affects the development of peripheral allergy-relevant stem cells in the blood. In order to present this result Dr. Irina Lehmann and Dr. Kristin Weie chose a new scientific path: The combination of exposure analysis and stem cell research.

Stem cells are not specialised, propagate without limit and can develop to different cell types. From these the different cell and tissue types of the human organism, including the allergy-promoting eosinophil granulocytes, are differentiated. Progenitor cells, e.g. eosinophil/basophilic progenitors, which mature in the bone marrow and are then washed out into the bloodstream -- the so-called periphery -- function as a link between unspecialised stem cells and specialised tissue and organ cells. Until now, whether and to what extent environmental contaminants affect this maturation and release has not been investigated.

The UFZ team of Dr. Irina Lehmann and Dr. Kristin Weie undertook their investigations from this point. Two facts were already known from a number of earlier studies: Firstly that the blood of allergy sufferers -- whether children or adults -- shows evidence of increased eosinophil/basophil progenitor levels. Secondly, that the occurrence of such peripheral progenitors in the blood of the umbilical cord indicates a higher risk for subsequent allergies. For the first time, the hypothesis which Dr. Kristin Weie and Dr. Irina Lehmann developed on this basis combined this knowledge from stem cell research with the results of many years of exposure research at the UFZ. The researchers characterise their approach in the following way: "We wanted to clarify the relationship between environmental influences and the maturation and differentiation of the progenitor cells on the one hand and its contribution to the occurrence of allergies on the other hand. Specifically, we wanted to know whether the occurrence of allergy-relevant progenitor cells in the blood of infants can be changed by environmental influences."

The results of the study, based on the data collected from 60 children aged one year, were recently published in the British medical journal "Clinical & Experimental Allergy": It was found that children with skin manifestations, such as atopic dermatitis or cradle cap, have increased levels of eosinophil progenitors in their blood. In this connection, it was shown for the first time that children already afflicted show particularly sensitive reactions when exposed to environmental contaminants: The offspring of families exposed to significant levels of volatile organic compounds (VOC) at home were found to have considerably higher allergy-relevant eosinophilic/basophilic progenitor cell levels. "That VOCs, large amounts of which are released with cigarette smoke, have the greatest effect on stem cells was not entirely unexpected," explains Dr. Irina Lehmann. "Just as important, however," adds Dr. Kristin Weie, is "that we can show that alterations in the number of stem cells as a result of harmful substances take place only in children who have already been afflicted with skin manifestations." This leads to the conclusion: There is a relationship between the genetic predisposition for a disease and environmental influences -- there are environmental and life style factors which determine whether a genetic predisposition is in fact realised or not.

Considerable logistical effort underlies this knowledge: On the one hand there is the long-term study "LiNA -- Life Style and Environmental Factors and their Influence on The Risk of Allergy" in Newborn Children, a joint project of the Helmholtz Centre for Environmental Research and the Stdtisches Klinikum St. Georg in Leipzig. 622 mothers, with a total of 629 children born, were recruited for the study between 2006 and 2008. In order to also take prenatal environmental influences into account -- in contrast with earlier comparable studies of newborn children -- mothers were already included in the investigations during pregnancy and the children from the time of birth. At the same time, it was necessary to become familiar with the methods required for stem cell analysis at the laboratory of the Canadian cooperation partner, Professor Judah Denburg of the McMaster University in Hamilton and to transfer this knowledge to Germany. Dr. Kristin Weie spent six months in Canada working in the group of Professor Denburg in order to acquire the necessary know-how and profit from the experience of the Canadian partners. Dr. Lehmann and Dr. Weie agree that "with the subject of environmental contamination and stem cells we have established an exciting new field of research." The UFZ team is currently the only one in the world investigating this relationship with analytical precision and methodical patience. The LiNA study, in the course of which mothers and their children can be observed over several years, represents a unique basis.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Helmholtz Centre For Environmental Research - UFZ.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Follow this link:
Smoking affects allergy-relevant stem cells

Public release date: 15-Nov-2012 [ | E-mail | Share ]

Contact: Bonnie Prescott bprescot@bidmc.harvard.edu 617-667-7306 Beth Israel Deaconess Medical Center

BOSTON Mesenchymal stem cells (MSCs), are a newly emerging cellular therapy being tested in approximately 250 clinical trials worldwide to help repair damaged tissues, such as injured heart muscle following a heart attack. The problem is that when culture-expanded MSCs are injected into the circulation, they have trouble gaining access to the inflamed tissuesexactly where their help is needed.

Now, research led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women's Hospital (BWH) reveals new insights into how MSCs "traffic" from the circulation into the tissue, providing important clues that could be used to improve the delivery of this promising therapy. The findings are published in the November issue of the journal Stem Cells.

MSCs have great clinical potential due to their convenient isolation, their lack of significant immunogenicity (allowing for transplantation between individuals), their lack of ethical controversy, their potential to differentiate into tissue-specific cell types, and their ability to promote blood vessel growth. The cells can seek out and repair damaged tissue and treat inflammation resulting from cardiovascular disease, brain and spinal cord injury, cartilage and bone injury, Crohn's disease, and other conditions. Given the systemic nature of many diseases and the desire for minimally invasive therapies, systemic infusion of MSCs holds considerable promise as an effective treatment in many conditions.

But, as senior author Christopher Carman, PhD, explains, in order for MSCs circulating in the bloodstream to have any therapeutic effect, they must first cross the vascular endothelium, the layer of cells that line blood vessels and serve as the primary barrier between the blood and the tissues. Carman and co-corresponding author Jeffrey Karp, PhD, set out to answer the question, "How do MSCs interact with this layer?"

"Our basic approach was to grow isolated endothelial monolayers in the lab in ways that mimic the vascular barrier structure in the body and conduct dynamic high-resolution imaging studies of MSCs interacting with the endothelium under normal or inflamed conditions," explains Carman, an investigator in BIDMC's Center for Vascular Biology Research and Assistant Professor of Medicine at Harvard Medical School (HMS).

Their experiments revealed that, similar to white blood cells that act during an immune response, MSCs use inflammation-specific adhesion molecules called vascular cell adhesion molecule-1 (VCAM-1) to stick to the endothelium at sites of inflammation. "But," says Carman, "whereas white cells very efficiently crawl over the endothelial surface, apparently searching out weak spots to breach and migrate across this barrier, we discovered that MSCs are unable to mediate such crawling and are about 10 times slower to cross the endothelium." And that, he adds, may explain why MSCs are not efficient at entering inflamed tissues.

"This work suggests that the initial phase of the homing cascadecell rollingis the rate limiting step to achieve effective homing for MSCs," says Karp, Co-Director of the Center for Regenerative Therapeutics at BWH, and Associate Professor of Medicine at HMS. (Homing occurs when circulating MSCs target areas of injury in response to signals of cellular damage; cell rolling refers to the way that MSCs "decelerate" on this target tissue.)

"Clinically this would be a good place to focus efforts to enhance MSC homingto improve the ability to roll on inflamed endothelium, since we showed that MSCs can efficiently adhere under static conditions and transmigrate on the endothelium in inflamed tissues," adds Karp, who is also a principal faculty member of the Harvard Stem Cell Institute.

Go here to see the original:
Study reveals insights that could aid in therapeutic use of mesenchymal stem cells

Northern White Rhinoceros. Credit: San Diego Zoo

Starting with normal skin cells, scientists from The Scripps Research Institute have produced the first stem cells from endangered species. Such cells could eventually make it possible to improve reproduction and genetic diversity for some species, possibly saving them from extinction, or to bolster the health of endangered animals in captivity.

A description of the accomplishment appeared in an advance online edition of the journal Nature Methods on September 4, 2011.

Genesis

About five years ago, Oliver Ryder, PhD, the director of genetics at the San Diego Zoo Institute for Conservation Research, contacted Jeanne Loring, PhD, professor of developmental neurobiology at Scripps Research, to discuss the possibility of collecting stem cells from endangered species. Ryder's team had already established the Frozen Zoo, a bank of skin cells and other materials from more than 800 species and wondered if the thousands of samples they had amassed might be used as starting points.

Just as is hoped with humans, Ryder thought stem cells from endangered species might enable lifesaving medical therapies or offer the potential to preserve or expand genetic diversity by offering new reproduction possibilities.

At the time, although researchers were working with stem cells from embryos, scientists had not yet developed techniques for reliably inducing normal adult cells to become stem cells. But the technology arrived soon after, and scientists now accomplish this feat, called induced pluripotency, by inserting genes in normal cells that spark the transformation.

While Loring's team met with Ryder in early 2008, they realized that these newly emerging techniques might be applied to endangered species. Postdoctoral fellow Inbar Friedrich Ben-Nun, PhD, set out to systematically explore the possibilities.

Ryder suggested two species for initial work. The first was a highly endangered primate called a drill that he chose because of its close genetic connection to humans, and because in captivity the animals often suffer from diabetes, which researchers are working to treat in humans using stem cell-based therapies.

The northern white rhinoceros was the second candidate. Ryder chose this animal because it is genetically far removed from primates, and because it is one of the most endangered species on the planet. There are only seven animals still in existence, two of which reside at the San Diego Zoo Safari Park.

Link:
Scientists produce first stem cells from endangered species

Dead and damaged heart muscle may be replaced with stem cells from the heart itself, if a new chemical discovered by La Jolla-based scientists lives up to its promise.

The chemical, called IDT-1, turns mouse and human embryonic stem cells into an unlimited number of heart muscle cells, called cardiomyocytes. The scientists say it might yield a drug to repair damage from heart attacks and from cardiac fibrosis, or scarring in heart tissue.

A study on the findings was published Nov. 6 in the Journal of Medicinal Chemistry. Its authors include Dennis Schade and John Cashman of the Human BioMolecular Institute, along with Mark Mercola of the Sanford-Burnham Medical Research Institute.

The three are working with ChemRegen, a private La Jolla biotech company established by Cashman and colleagues, to see if a drug can be produced from the research.

If such a drug does emerge, it could become a blockbuster. Heart disease was the leading cause of death in the United States last year, with nearly 600,000 deaths, according to the U.S Centers for Disease Control and Prevention in Atlanta.

Hearts contain their own stem cells. While these cells could repair the damage from a heart attack, they don't, Cashman said.

"They need to be stimulated," he said. "They need to have a good reason to turn into heart cells."

The IDT-1 chemical blocks the activity of a substance called transforming growth factor-beta usually present in stem cells. This lack of activity starts the stem cells down the road into becoming heart cells.

But before ChemRegen can start clinical trials on a drug based on IDT-1, it must be tested for toxicity and taken through animal studies to see if it provides therapeutic benefit," Cashman said. All told, that may cost about $3 million to $4 million, with $1 million going for toxicology studies and the rest for animal studies. ChemRegen plans to seek partnerships with drug companies or other investors to fund that work.

IDT-1 is what the drug industry calls a small molecule, which has a relatively simple structure. In contrast, biotech products often are made up of large protein molecules, DNA, or even whole cells. Cashman said having a small molecule to work with should be a plus for pharmaceutical companies, because they're experienced in making such drugs.

Read more:
New chemical may spur heart repair

Choice of the Week #65288;Week of November 12, 2012 programs #65289;
#9632;Science View #65374; How Buildings Handled Japan #39;s 2011 Megaquake #65374; On that day, cameras across Japan captured the earth shaking, buildings swaying and collapsing. Through analysis of these videos, complex tremors were found to be generated from three seismic sources, and destroyed certain weak points of buildings. #9632;Battling Back #65374; The Festival of Samurai Horsemen #65374; Fukushima takes pride in its annual samurai festival that is said to be over 1000 years old. But last year, the area was devastated by the earthquake, tsunami and nuclear crisis... Horses, armors, and people #39;s lives were lost. Will the locals revive their treasured event? #9632;NHK Documentary #65374; Shinya Yamanaka, Nobel Winner : The iPS Cell Revolution #65374; Last month, Professor Shinya Yamanaka of Kyoto University was announced to receive the Nobel Prize for his work with stem cells, which might overturn biological science and revolutionize medical care. Professor Yamanaka discusses what exactly iPS cells are, along with his struggles and triumphs.From:NHKWorldViews:2 0ratingsTime:01:31More inEntertainment

Visit link:
Choice of the Week（Week of November 12, 2012 programs） - Video